KRAS mutation status critically determines the clinical outcome of patients with KMT2A‐rearranged acute myeloid leukemia
Authors:
Abstract
Background: KMT2A(11q23)‐rearranged acute myeloid leukemia (KMT2A‐r AML) represents a clinically aggressive subtype with heterogeneous outcomes. Current evidence remains inconclusive regarding the prognostic relevance of fusion partners in 11q23/KMT2A‐rearranged AML. The comprehensive mutational landscape and prognostic implications of co‐occurring driver mutations remain poorly characterized.Methods: A comprehensive clinicogenomic analysis of 159 de novo KMT2A‐r AML patients was conducted to assess the correlation between molecular profiles and clinical outcomes.Results: Notably, the KMT2A::MLLT4 subgroup exhibited significantly higher KRAS mutation frequencies compared to other rearrangement groups (p < .05). Survival analysis revealed that the KMT2A::MLLT4 cohort demonstrated trends toward inferior overall survival (OS) and increased cumulative incidence of relapse (CIR) relative to other rearrangement subgroups. Stratified by mutational status, patients with KRAS mutations exhibited significantly inferior 2‐year OS rates (24.6% vs. 50.5%; p = .001) and higher 2‐year CIR (56.3% vs. 34.6%; p = .018) compared to KRAS wild‐type counterparts. This adverse prognostic association remained in the transplanted cohort (OS: 32.3% vs. 73.5%; p < .001; CIR: 73.6% vs. 23.0%; p < .001). In contrast, mutations in NRAS, FLT3 did not demonstrate statistically significant associations with OS or CIR in either the overall cohort or transplant subgroup. Multivariable Cox regression confirmed KRAS mutation as an independent adverse prognostic factor for both 2‐year OS (hazard ratio [HR], 0.51; 95% CI, 0.31–0.84; p = .008) and CIR (HR, 1.80; 95% CI, 1.04–3.12; p = .037) in the overall cohort. This association persisted in the transplanted patients subgroup (OS: HR, 0.18; 95% CI, 0.06–0.52; p = .001; CIR: HR, 3.89; 95% CI, 1.05–14.37; p = .042).Conclusions: These results demonstrate the independent prognostic value of KRAS mutations across treatment modalities, including both conventional chemotherapy and hematopoietic stem cell transplantation.Keywords
Funding Information
- National Natural Science Foundation of China (82170205, 82300240)
This publication has 24 references indexed in Scilit:
- Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 updateCancer Letters, 2024
- Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY studyLeukemia, 2024
- Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangementsCancer Medicine, 2022
- Comprehensive immunophenotypic study of acute myeloid leukemia with KMT2A (MLL) rearrangement in adults: A single‐institution experienceCytometry Part B: Clinical Cytometry, 2021
- The MLL recombinome of acute leukemias in 2017Leukemia, 2017
- KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in CancerCell, 2017
- Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignanciesCancer, 2016
- Loss of Dnmt3a and endogenous KrasG12D/+ cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesisLeukemia, 2015
- MLL translocations, histone modifications and leukaemia stem-cell developmentNature Reviews Cancer, 2007
- Competing risk analysis using R: an easy guide for cliniciansBone Marrow Transplantation, 2007